Seeking better outcomes for patients
CytRx Corporation is a biopharmaceutical company focused on the discovery and development of new therapeutics to treat patients with high unmet medical needs
CytRx has both near-term potential milestone/royalty payments and a pipeline of additional next-gen candidates
Aldoxorubicin: 1st Gen LADR Partnered with ImmunityBio Trials have proven safety of higher dosing and efficacy
CytRx milestones and royalties from KemPharm for Arimoclomol
